Pharmafile Logo
Pharmafocus logo
Advanced Search

schizophrenia

Showing 14 posts of 29 posts found.

janssen_latest_logo_on_sign_closer

Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia

June 2, 2016
Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia

Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia.  Trevicta …

News
heptares_logo

Heptares announces positive early-stage dementia trial results

February 10, 2016
Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia

Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …

News
aristada

FDA approves Alkermes schizophrenia treatment

October 6, 2015
Research and Development Alkermes, Aristada, FDA, schizophrenia

The US Food and Drug Administration (FDA) has approved Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada …

News
Rexulti (brexpiprazole)

FDA approves Lundbeck and Otsuka’s Rexulti for depression

July 14, 2015
Sales and Marketing FDA, Lundbeck, Otsuka, Rexulti, US, brexpiprazole, depression, major depressive disorder, schizophrenia

Lundbeck and Otsuka have gained a yes vote from the FDA for their jointly-marketed antidepressant, Rexulti. The US regulator approved …

News

FDA accepts new schizophrenia drug filing

September 24, 2014
Sales and Marketing FDA, Lundbeck, Otsuka, brexpiprazole, depression, schizophrenia

The FDA is reviewing Otsuka and Lundbeck’s brexpiprazole for the treatment of schizophrenia and as an adjunctive therapy for the …

News
abilify_bms_otsuka

Alkermes schizophrenia drug shines in Phase III

April 8, 2014
Medical Communications, Research and Development, Sales and Marketing Abilify, Alkermes, aripiprazole, schizophrenia

Alkermes’ investigational schizophrenia drug has met its primary endpoint in a pivotal trial, leading the firm to seek regulatory approval …

News
Roche image

Roche schizophrenia drug fails

January 21, 2014
Research and Development, Sales and Marketing Roche, biopertin, schizophrenia

Roche’s investigational schizophrenia drug bitopertin has failed to help patients with the disorder’s negative symptoms when pitted against placebo. Two …

News

GMP certification bodes well for Alexza’s lead product

August 28, 2012
Manufacturing and Production Alexza, FDA, GMP, schizophrenia

US drugmaker Alexza Pharmaceuticals’ manufacturing facility for lead product Adasuve has been given a green light from the Spanish medicine …

News

Janssen’s monthly antipsychotic approved in Europe

March 9, 2011
Sales and Marketing Janssen, Xeplion, antipsychotic, injectible antipsychotic, paliperidone palmitate, schizophrenia

Janssen’s injectable antipsychotic Xeplion has been approved by the European Commission for the treatment of schizophrenia. There is no cure …

News

NICE decides to back Abilify in schizophrenia

January 27, 2011
Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia

NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …

News

Janssen’s Invega wins schizoaffective approval in Europe

January 6, 2011
Sales and Marketing Invega, Janssen, paliperidone ER, schizoaffective disorder, schizophrenia

Janssen’s Invega has become the first drug to be licensed in Europe to treat schizoaffective disorder. European regulators approved Invega …

News

Roche highlights R&D promise after setbacks

December 9, 2010
Research and Development MS, Roche, oncology, personalised medicine, schizophrenia

Roche has presented its pipeline to shareholders to boost confidence that it can sustain the spectacular growth of recent years. …

News

NICE issues schizophrenia commissioning guide

January 14, 2010
NICE, commissioning, schizophrenia

NICE has published a commissioning guide to help primary and secondary care teams recognise, treat and manage adult schizophrenia. The …

News

The management of schizophrenia

October 14, 2003
Sales and Marketing NICE, clinical guidelines, healthcare, schizophrenia

The publication of NICE's clinical guidelines on the management of schizophrenia in December marks a significant milestone – the first …

Feature

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024